T lymphocyte receptor recognizing KRAS G12V peptide–MHC complex (KRAS G12V-specific TCR)

The T lymphocyte receptor recognizing KRAS G12V peptide–MHC complex is a recombinant or naturally-derived T cell receptor (TCR) that specifically binds to a peptide containing the KRAS G12V mutation presented by specific human leukocyte antigen (HLA) molecules, usually HLA-A*11:01 or HLA-A*03:01. These TCRs can be expressed in autologous or allogeneic T cells, redirecting them to target and kill tumor cells presenting this neoantigen, and form the basis for highly specific adoptive T cell therapies and TCR-mimic antibody approaches for cancers harboring the KRAS G12V mutation. Such TCRs exhibit high specificity and functional activity, typically with little to no cross-reactivity to wild-type KRAS, minimizing risk of off-tumor effects. They can be used in combination with immune checkpoint inhibitors and represent a rapidly advancing frontier in precision immuno-oncology.

Other names

KRAS G12V-specific T cell receptorKRAS G12V TCRKRAS G12V neoantigen-specific TCRTCR recognizing KRAS G12V peptide/MHCHLA-A*11:01–restricted KRAS G12V TCRHLA-A*03:01–restricted KRAS G12V TCR

Recognition of KRAS G12V peptide presented by HLA molecules on tumor cells, leading to T cell activation, cytokine release, and tumor cell lysis. Redirected cytotoxicity (via engineered TCR-T cells or TCRm antibodies). Synergistic activity with immune checkpoint blockade (e.g., anti-PD-1).